FeesSafety
Pluang+

Medicenna reports strong clinical results for MDNA11 and bizaxofusp, advancing cancer and autoimmune therapies.

Company Fundamentals
17 Nov 2026, 14:45 WIB
GlobeNewsWire
View Source
Bullish
Medicenna reports strong clinical results for MDNA11 and bizaxofusp, advancing cancer and autoimmune therapies.

Medicenna Therapeutics announced completion of enrollment in its Phase 1/2 ABILITY-1 trial for MDNA11, showing a 40% objective response rate in biomarker-enriched gastrointestinal cancers and promising results in ICI-resistant melanoma. Bizaxofusp Phase 2b data showed a median overall survival of 13.7 months in recurrent glioblastoma patients, nearly doubling survival compared to controls. MDNA209 demonstrated potent preclinical efficacy in autoimmune disease models. The company plans regulatory discussions for MDNA11 and partnership pursuits for bizaxofusp and MDNA209 while managing cash flow and seeking additional financing to support ongoing development.

Medicenna Therapeutics' recent trial results provide context for healthcare developments. For readers following the health sector, here is Pluang's market snapshot as of Nov 17, 2026 18:51 WIB: out of 150 priced US health stocks, 51 rose and 91 fell. Notable movers include CGC at USD 0.56 (+2.56%, 45% Sell / 55% Buy, typical hold time 40 days), INO at USD 1.43 (+2.14%, 89% Sell / 11% Buy, typical hold time 41 days), and DYN at USD 16.35 (-2.10%, typical hold time 13 days).

More News

Adagene and City of Hope launch Phase 1 trial for new colorectal cancer combo therapy.

Adagene and City of Hope launch Phase 1 trial for new colorectal cancer combo therapy.

Adagene Inc. and City of Hope have started a Phase 1 clinical trial testing a new combination therapy for metastatic colorectal cancer patients resistant to standard treatments. The trial evaluates two experimental drugs, ivonescimab and muzastotug (...

Others
Bullish
58 minutes ago
Provident Bank appoints three leaders to boost commercial banking growth and services.

Provident Bank appoints three leaders to boost commercial banking growth and services.

Provident Bank announced three key leadership appointments to strengthen its Commercial Banking division. Edward Galan will lead Middle Market Lending, Dawn Scocco will manage portfolio and credit risk, and John Maio will head Treasury Management Ser...

Market News
Bullish
58 minutes ago
RoyaLand launches its first mobile game Palazzo Chronicles: Match 3 on Google Play.

RoyaLand launches its first mobile game Palazzo Chronicles: Match 3 on Google Play.

RoyaLand Company Ltd. has released its first mobile game, Palazzo Chronicles: Match 3, on the Google Play Store. The free-to-play match-3 puzzle game features over 270 levels where players restore a royal palace set in Risorgimento Italy. This launch...

Others
Bullish
58 minutes ago
Atiq Khan joins Dune as Director of Engineering to lead real-time onchain market data development.

Atiq Khan joins Dune as Director of Engineering to lead real-time onchain market data development.

Atiq Khan, with over 25 years in financial technology including roles at Goldman Sachs and Coinbase, has joined Dune as Director of Engineering. He will lead the engineering efforts behind Dune Market Data Feeds, which provide real-time trade and liq...

Others
Bullish
58 minutes ago
BlackRock increases voting rights in ICG PLC to 5.16% as of November 13, 2026

BlackRock increases voting rights in ICG PLC to 5.16% as of November 13, 2026

BlackRock, Inc. has increased its total voting rights in ICG PLC to 5.16% as of November 13, 2026, up from 5.17% previously reported. This includes 5.08% voting rights attached to shares and 0.08% through financial instruments. The notification was o...

Market News
Neutral
58 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App